Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.
World of DTC Marketing
MAY 16, 2022
Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. According to Lilly side, the effects include “Mounjaro may cause tumors in the thyroid, including thyroid cancer and Inflammation of the pancreas (pancreatitis).”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 17, 2022
A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025.
European Pharmaceutical Review
OCTOBER 12, 2022
This is promising when side effects such as ARIAs are often detected in magnetic resonance imaging brain scans of patients who are given the antibodies. If the drug is approved, GlobalData estimates that global sales for HMTM will reach $127 million by 2030.
World of DTC Marketing
JANUARY 7, 2021
By 2030, low retention will, on average, cost the US $430 billion annually. The title-seeking job hoppers will always be a pharma side-effect, but who within the big matrix organizations are really trying to change the way they do business every day? Employee retention rates hit a record low in March 2020.
Medico Reach
FEBRUARY 8, 2023
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. from 2023 to 2030. Poised to grow at a CAGR of 29.4% The global pharmacovigilance (PV) market stood at USD 7.80
pharmaphorum
SEPTEMBER 30, 2022
GlobalData notes that the side effect could be a barrier for lecanemab use as it will require patient monitoring, but points out that the rates are a “significant improvement” on Aduhelm, which had an ARIA-E rate of 35% of patients taking the approved dose in clinical trials. .”
Expert insights. Personalized for you.
59 
Let's personalize your content